NADAC acquisition cost data for TADALAFIL 10 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 66993070230 | $0.4501 | 2022-02-23 | Rx |
| 66993070230 | $0.4501 | 2022-02-23 | Rx |
| 66993070230 | $0.4501 | 2022-02-23 | Rx |
| 66993070230 | $0.4501 | 2022-02-23 | Rx |
| 00093301856 | $0.3542 | 2022-12-21 | Rx |
| 13668056730 | $0.3542 | 2022-12-21 | Rx |
| 16714007601 | $0.3542 | 2022-12-21 | Rx |
| 16729037110 | $0.3542 | 2022-12-21 | Rx |
| 16729037116 | $0.3542 | 2022-12-21 | Rx |
| 27241011303 | $0.3542 | 2022-12-21 | Rx |
Generic: Tadalafil | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $158.4M | 272,296 | 58,286 | $13.37 |
| 2020 | $94.9M | 278,247 | 57,729 | $6.78 |
| 2021 | $103.1M | 274,055 | 59,582 | $8.08 |
| 2022 | $103.4M | 289,882 | 65,301 | $7.43 |
| 2023 | $95.2M | 316,347 | 74,638 | $6.57 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $13.8M | 46,293 | 11,280 |
| New York | $13.2M | 28,721 | 6,720 |
| Florida | $6.7M | 61,099 | 14,581 |
| Pennsylvania | $5.5M | 13,883 | 3,112 |
| Ohio | $5.0M | 9,127 | 2,264 |
| Texas | $4.5M | 14,250 | 3,523 |
| Massachusetts | $3.2M | 6,229 | 1,327 |
| South Carolina | $2.9M | 6,831 | 1,532 |
| North Carolina | $2.3M | 7,596 | 1,791 |
| Georgia | $2.1M | 6,224 | 1,448 |
| Michigan | $2.0M | 7,407 | 1,990 |
| Virginia | $1.9M | 5,515 | 1,475 |
| Illinois | $1.9M | 6,510 | 1,710 |
| Missouri | $1.9M | 4,243 | 930 |
| Tennessee | $1.8M | 4,010 | 958 |
| Arizona | $1.7M | 4,384 | 1,102 |
| Colorado | $1.7M | 6,380 | 1,336 |
| Minnesota | $1.6M | 2,463 | 561 |
| New Jersey | $1.5M | 10,343 | 2,768 |
| Indiana | $1.5M | 4,037 | 937 |
| Connecticut | $1.4M | 4,215 | 928 |
| Maryland | $1.4M | 4,328 | 1,098 |
| Wisconsin | $1.4M | 3,248 | 717 |
| Alabama | $1.1M | 3,650 | 819 |
| Washington | $1.1M | 2,893 | 765 |
| Kentucky | $896.1K | 2,184 | 515 |
| Louisiana | $893.2K | 2,735 | 549 |
| Oregon | $883.3K | 3,274 | 842 |
| Kansas | $843.0K | 1,667 | 338 |
| Oklahoma | $836.9K | 1,857 | 422 |
| District of Columbia | $833.6K | 1,050 | 254 |
| Utah | $783.4K | 1,402 | 379 |
| Mississippi | $635.9K | 1,173 | 251 |
| Nevada | $623.6K | 1,615 | 420 |
| Arkansas | $480.0K | 1,402 | 349 |
| New Mexico | $458.3K | 1,110 | 243 |
| Nebraska | $420.1K | 730 | 158 |
| Iowa | $407.8K | 1,417 | 312 |
| Vermont | $381.2K | 953 | 250 |
| New Hampshire | $357.0K | 1,529 | 384 |
| Rhode Island | $351.0K | 736 | 149 |
| Maine | $323.0K | 800 | 198 |
| Puerto Rico | $320.7K | 11,435 | 3,038 |
| Hawaii | $258.0K | 883 | 218 |
| Delaware | $255.0K | 733 | 211 |
| North Dakota | $202.7K | 221 | 60 |
| West Virginia | $201.8K | 909 | 233 |
| Montana | $145.0K | 421 | 122 |
| Idaho | $142.0K | 570 | 170 |
| South Dakota | $136.2K | 366 | 80 |
| Alaska | $77.8K | 978 | 321 |
| Wyoming | $40.7K | 149 | 47 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.